The release of the final appraisal document (FAD) for this topic has been suspended. This is because the company (Merck Sharp & Dohme) is proposing an updated value proposition for pembrolizumab and additional evidence about the clinical use of pembrolizumab monotherapy and combination therapy. This means that the basis for the decision-making is likely to change.
Further details regarding the next steps (such as an appraisal committee meeting) and timings of this topic will be available in due course.